Literature DB >> 11224867

Surgical strategy for spinal metastases.

K Tomita1, N Kawahara, T Kobayashi, A Yoshida, H Murakami, T Akamaru.   

Abstract

STUDY
DESIGN: A new surgical strategy for treatment of patients with spinal metastases was designed, and 61 patients were treated based on this strategy.
OBJECTIVES: To propose a new surgical strategy for the treatment of patients with spinal metastases. SUMMARY OF BACKGROUND DATA: A preoperative score composed of six parameters has been proposed by Tokuhashi et al for the prognostic assessment of patients with metastases to the spine. Their scoring system was designed for deciding between excisional or palliative procedures. Recently, aggressive surgery, such as total en bloc spondylectomy for spinal metastases, has been advocated for selected patients. Surgical strategies should include various treatments ranging from wide or marginal excision to palliative treatment with hospice care.
METHODS: Sixty-seven patients with spinal metastases who had been treated from 1987-1991 were reviewed, and prognostic factors were evaluated retrospectively (phase 1). A new scoring system for spinal metastases that was designed based on these data consists of three prognostic factors: 1) grade of malignancy (slow growth, 1 point; moderate growth, 2 points; rapid growth, 4 points), 2) visceral metastases (no metastasis, 0 points; treatable, 2 points: untreatable, 4 points), and 3) bone metastases (solitary or isolated, 1 point; multiple, 2 points). These three factors were added together to give a prognostic score between 2-10. The treatment goal for each patient was set according to this prognostic score. The strategy for each patient was decided along with the treatment goal: a prognostic score of 2-3 points suggested a wide or marginal excision for long-term local control; 4-5 points indicated marginal or intralesional excision for middle-term local control; 6-7 points justified palliative surgery for short-term palliation; and 8-10 points indicated nonoperative supportive care. Sixty-one patients were treated prospectively according to this surgical strategy between 1993-1996 (phase 2). The extent of the spinal metastases was stratified using the surgical classification of spinal tumors, and technically appropriate and feasible surgery was performed, such as en bloc spondylectomy, piecemeal thorough excision, curettage, or palliative surgery.
RESULTS: The mean survival time of the 28 patients treated with wide or marginal excision was 38.2 months (26 had successful local control). The mean survival time of the 13 patients treated with intralesional excision was 21.5 months (nine had successful local control). The mean survival time of the 11 patients treated with palliative surgery and stabilization was 10.1 months (eight had successful local control). The mean survival time of the patients with terminal care was 5.3 months.
CONCLUSIONS: A new surgical strategy for spinal metastases based on the prognostic scoring system is proposed. This strategy provides appropriate guidelines for treatment in all patients with spinal metastases.

Entities:  

Mesh:

Year:  2001        PMID: 11224867     DOI: 10.1097/00007632-200102010-00016

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  314 in total

1.  Clinical profile of long-term survivors of breast or thyroid cancer with metastatic spinal tumours.

Authors:  Y Kasai; E Kawakita; A Uchida
Journal:  Int Orthop       Date:  2006-04-26       Impact factor: 3.075

Review 2.  [Vertebral body replacement in spine surgery].

Authors:  F Kandziora; K J Schnake; C K Klostermann; N P Haas
Journal:  Unfallchirurg       Date:  2004-05       Impact factor: 1.000

3.  Modified total en bloc spondylectomy in thoracic vertebra tumour.

Authors:  Changan Guo; Zuoqin Yan; Jian Zhang; Chun Jiang; Jian Dong; Xiaoxing Jiang; Qinming Fei; Dehua Meng; Zhengrong Chen
Journal:  Eur Spine J       Date:  2010-11-13       Impact factor: 3.134

Review 4.  Management of metastatic sacral tumours.

Authors:  Nasir A Quraishi; Kyriakos E Giannoulis; Kimberley L Edwards; Bronek M Boszczyk
Journal:  Eur Spine J       Date:  2012-06-23       Impact factor: 3.134

5.  Clinical outcome of posterior fixation surgery in patients with vertebral metastasis of lung cancer.

Authors:  Tomoyuki Igarashi; Keigo Okamoto; Koji Teramoto; Ryosuke Kaku; Keiko Ishida; Keiko Ueda; Yo Kawaguchi; Tetsuo Hori; Masayuki Hashimoto; Shoji Kitamura; Noriaki Tezuka; Jun Hanaoka
Journal:  Mol Clin Oncol       Date:  2017-03-17

6.  Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases.

Authors:  Karl-Ake Jansson; Henrik C F Bauer
Journal:  Eur Spine J       Date:  2005-03-03       Impact factor: 3.134

7.  Outcome of embolised vascular metastatic renal cell tumours causing spinal cord compression.

Authors:  N A Quraishi; S Purushothamdas; S R Manoharan; G Arealis; R Lenthall; M P Grevitt
Journal:  Eur Spine J       Date:  2013-01-18       Impact factor: 3.134

8.  Clinical significance of traditional clinical parameters and inflammatory biomarkers for the prognosis of patients with spinal chondrosarcoma: a retrospective study of 150 patients in a single center.

Authors:  Kehan Xu; Bo Li; Quan Huang; Dongjie Jiang; Haitao Sun; Nanzhe Zhong; Wei Wan; Haifeng Wei; Jianru Xiao
Journal:  Eur Spine J       Date:  2019-05-04       Impact factor: 3.134

9.  Preoperative prediction for regaining ambulatory ability in paretic non-ambulatory patients with metastatic spinal cord compression.

Authors:  M Ohashi; T Hirano; K Watanabe; K Katsumi; H Shoji; A Sano; H Tashi; I Takahashi; M Wakasugi; Y Shibuya; N Endo
Journal:  Spinal Cord       Date:  2016-10-18       Impact factor: 2.772

10.  Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study.

Authors:  Ori Barzilai; Anne L Versteeg; Arjun Sahgal; Laurence D Rhines; Mark H Bilsky; Daniel M Sciubba; James M Schuster; Michael H Weber; Peter Pal Varga; Stefano Boriani; Chetan Bettegowda; Michael G Fehlings; Yoshiya Yamada; Michelle J Clarke; Paul M Arnold; Ziya L Gokaslan; Charles G Fisher; Ilya Laufer
Journal:  Cancer       Date:  2018-11-29       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.